دورية أكاديمية
أعرض في EDS

Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study.

التفاصيل البيبلوغرافية
العنوان: Effectiveness of BNT162b2 Against Infection, Symptomatic Infection, and Hospitalization Among Older Adults Aged ≥65 Years During the Delta Variant Predominance in Japan: The VENUS Study.
المؤلفون: Mimura W; Section of Clinical Epidemiology, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine., Ishiguro C; Section of Clinical Epidemiology, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine., Terada-Hirashima J; Department of Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine., Matsunaga N; AMR Clinical Reference Center, National Center for Global Health and Medicine., Sato S; Clinical Research Center, Nagasaki University Hospital., Kawazoe Y; Clinical Research Center, Nagasaki University Hospital., Maeda M; Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences., Murata F; Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences., Fukuda H; Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences.
المصدر: Journal of epidemiology [J Epidemiol] 2024 Jun 05; Vol. 34 (6), pp. 278-285. Date of Electronic Publication: 2024 Jan 31.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Japan Epidemiological Association Country of Publication: Japan NLM ID: 9607688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-9092 (Electronic) Linking ISSN: 09175040 NLM ISO Abbreviation: J Epidemiol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2018- : [Tokyo] : Japan Epidemiological Association
Original Publication: Tokyo : Japan Epidemiological Association
مواضيع طبية MeSH: Hospitalization*/statistics & numerical data , COVID-19*/prevention & control , COVID-19*/epidemiology , BNT162 Vaccine* , Vaccine Efficacy*/statistics & numerical data, Humans ; Aged ; Japan/epidemiology ; Male ; Female ; Aged, 80 and over ; Cohort Studies ; SARS-CoV-2 ; COVID-19 Vaccines/administration & dosage
مستخلص: Background: We evaluated the effectiveness of the BNT162b2 vaccine against infection, symptomatic infection, and hospitalization in older people during the Delta-predominant period (July 1 to September 30, 2021).
Methods: We performed a population-based cohort study in an older adult population aged ≥65 years using data from the Vaccine Effectiveness, Networking, and Universal Safety Study conducted from January 1, 2019, to September 30, 2021, in Japan. We matched BNT162b2-vaccinated and -unvaccinated individuals in a 1:1 ratio on the date of vaccination of the vaccinated individual. We evaluated the effectiveness of the vaccine against infection, symptomatic infection, and coronavirus disease (COVID-19)-related hospitalization by comparing the vaccinated and unvaccinated groups. We estimated the risk ratio and risk difference using the Kaplan-Meier method with inverse probability weighting. The vaccine effectiveness was calculated as (1 - risk ratio) × 100%.
Results: The study included 203,574 matched pairs aged ≥65 years. At 7 days after the second dose, the vaccine effectiveness of BNT162b2 against infection, symptomatic infection, and hospitalization was 78.1% (95% confidence interval [CI], 65.2-87.8%), 79.1% (95% CI, 64.6-88.9%), and 93.5% (95% CI, 83.7-100%), respectively.
Conclusion: BNT162b2 was highly effective against infection, symptomatic infection, and hospitalization in Japan's older adult population aged ≥65 years during the Delta-predominant period.
References: Open Forum Infect Dis. 2022 Nov 24;9(12):ofac636. (PMID: 36589480)
Clin Infect Dis. 2022 Nov 30;75(11):1971-1979. (PMID: 35438137)
Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. (PMID: 35918782)
N Engl J Med. 2021 Apr 15;384(15):1412-1423. (PMID: 33626250)
BMJ. 2022 Feb 10;376:e069052. (PMID: 35144968)
Clin Infect Dis. 2023 Jan 6;76(1):18-24. (PMID: 36124762)
Lancet Reg Health West Pac. 2022 Nov;28:100571. (PMID: 35971514)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
N Engl J Med. 2022 Jan 27;386(4):340-350. (PMID: 35021002)
Prev Chronic Dis. 2021 Jul 01;18:E66. (PMID: 34197283)
BMJ. 1999 Dec 4;319(7223):1492-5. (PMID: 10582940)
Vaccines (Basel). 2022 May 14;10(5):. (PMID: 35632535)
Open Forum Infect Dis. 2020 Dec 28;8(2):ofaa638. (PMID: 33553477)
Cell Rep Med. 2022 Mar 11;3(4):100583. (PMID: 35480627)
Int J Infect Dis. 2022 Dec;125:58-60. (PMID: 36220547)
Glob Health Med. 2022 Apr 30;4(2):129-132. (PMID: 35586768)
Lancet Reg Health West Pac. 2022 Mar 29;23:100442. (PMID: 35359913)
JAMA Netw Open. 2022 Apr 1;5(4):e228526. (PMID: 35452106)
Lancet. 2022 Jun 25;399(10344):2351-2380. (PMID: 35405084)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Vaccine. 2022 Oct 6;40(42):6179-6186. (PMID: 36096969)
Lancet Infect Dis. 2022 Jan;22(1):35-42. (PMID: 34461056)
فهرسة مساهمة: Keywords: Delta variant; Japan; SARS-CoV-2 infection; cohort study; mRNA vaccine
المشرفين على المادة: 0 (BNT162 Vaccine)
0 (COVID-19 Vaccines)
SCR Organism: SARS-CoV-2 variants
تواريخ الأحداث: Date Created: 20230924 Date Completed: 20240605 Latest Revision: 20240607
رمز التحديث: 20240607
مُعرف محوري في PubMed: PMC11078592
DOI: 10.2188/jea.JE20230106
PMID: 37743530
قاعدة البيانات: MEDLINE
الوصف
تدمد:1349-9092
DOI:10.2188/jea.JE20230106